Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA, Feldman L, Seckler A, Wilson A. DiMasi JA, et al. Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Clin Pharmacol Ther. 2010. PMID: 20130567 Review.
New drug development in the United States from 1963 to 1990.
DiMasi JA, Bryant NR, Lasagna L. DiMasi JA, et al. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):471-86. doi: 10.1038/clpt.1991.172. Clin Pharmacol Ther. 1991. PMID: 1934860 No abstract available.
New indications for already-approved drugs: an analysis of regulatory review times.
DiMasi JA, Kaitin KI, Fernandez-Carol C, Lasagna L. DiMasi JA, et al. J Clin Pharmacol. 1991 Mar;31(3):205-15. doi: 10.1002/j.1552-4604.1991.tb04963.x. J Clin Pharmacol. 1991. PMID: 2019661
The notion of "acceptable risk": comment.
DiMasi JA. DiMasi JA. J Clin Epidemiol. 1988;41(9):939-43. doi: 10.1016/0895-4356(88)90111-4. J Clin Epidemiol. 1988. PMID: 3183699 No abstract available.
Success rates for new drugs entering clinical testing in the United States.
DiMasi JA. DiMasi JA. Clin Pharmacol Ther. 1995 Jul;58(1):1-14. doi: 10.1016/0009-9236(95)90066-7. Clin Pharmacol Ther. 1995. PMID: 7628176 No abstract available.
New drug development in the United States from 1963 to 1992.
DiMasi JA, Seibring MA, Lasagna L. DiMasi JA, et al. Clin Pharmacol Ther. 1994 Jun;55(6):609-22. doi: 10.1038/clpt.1994.78. Clin Pharmacol Ther. 1994. PMID: 8004878 No abstract available.
Risks, regulation, and rewards in new drug development in the United States.
DiMasi JA. DiMasi JA. Regul Toxicol Pharmacol. 1994 Apr;19(2):228-35. doi: 10.1006/rtph.1994.1021. Regul Toxicol Pharmacol. 1994. PMID: 8041920 Review. No abstract available.
Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994.
Gosse ME, DiMasi JA, Nelson TF. Gosse ME, et al. Among authors: dimasi ja. Clin Pharmacol Ther. 1996 Dec;60(6):608-18. doi: 10.1016/S0009-9236(96)90209-X. Clin Pharmacol Ther. 1996. PMID: 8988063 No abstract available.
Cost of innovation in the pharmaceutical industry.
DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. DiMasi JA, et al. J Health Econ. 1991 Jul;10(2):107-42. doi: 10.1016/0167-6296(91)90001-4. J Health Econ. 1991. PMID: 10113009
Rising research and development costs for new drugs in a cost containment environment.
DiMasi JA. DiMasi JA. Pharmacoeconomics. 1992;1(Suppl 1):13-20. doi: 10.2165/00019053-199200011-00006. Pharmacoeconomics. 1992. PMID: 10146926
47 results
Jump to page
Feedback